Rakuten on January 10
Zhengye Biotechnology Holding Limited（正业生物）日前递交招股书，准备在美国纳斯达克上市。
Zhengye Biotech has obtained the notice of filing for overseas issuance and listing. Zhengye Biotech intends to issue no more than 1,312,908 ordinary shares.
Zhengye Biotech is one of the first enterprises designated by the Ministry of Agriculture to produce highly pathogenic porcine PRRS inactivated vaccine and rabies purified lyophilized inactivated vaccine (Flury LEP strain), and is designated by the Ministry of Agriculture to produce swine fever splenic drenching attenuated vaccine.
According to the prospectus, the prospectus shows that the revenue of Zhengye Biotech in 2021 and 2022 will be 214 million yuan and 260 million yuan respectively, the operating profit will be 52.38 million yuan and 65.83 million yuan respectively, and the net profit will be 46.47 million yuan and 55.74 million yuan respectively.
Zhengye Biotech's revenue in the first half of 2023 was 117 million yuan (about US$16.115 million), compared with 123 million yuan (US$17.01 million) in the same period last year;
Zhengye Biotech's net profit in 2023 will be 24.07 million yuan (about 3.32 million US dollars), compared with 27.55 million yuan (about 3.8 million US dollars) in the same period last year.
IPO,Zhenfa Han 持丽97.5818%,Wei Lian持为0.1819 %,Yawen Dong 持股为0.2728%,Yuyou He持股为0.1096%。
———————————————
Lei Di was founded by Lei Jianping, a media person, if it is reprinted, please indicate the source.